X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
prostate cancer (230) 230
humans (223) 223
male (218) 218
urology & nephrology (173) 173
index medicus (160) 160
prostatic neoplasms - drug therapy (145) 145
intermittent androgen suppression (97) 97
cancer (95) 95
oncology (95) 95
androgen antagonists - therapeutic use (91) 91
intermittent (88) 88
aged (86) 86
care and treatment (77) 77
men (75) 75
testosterone (75) 75
prostate-specific antigen - blood (72) 72
prostatic neoplasms - pathology (72) 72
middle aged (66) 66
quality of life (65) 65
radical prostatectomy (65) 65
carcinoma (62) 62
suppression (61) 61
treatment outcome (60) 60
antigen (56) 56
therapy (55) 55
androgen antagonists - administration & dosage (54) 54
prostatic neoplasms - blood (54) 54
antineoplastic agents, hormonal - therapeutic use (53) 53
deprivation (50) 50
prostatic neoplasms - therapy (49) 49
metastasis (46) 46
urology (44) 44
androgens (43) 43
intermittent androgen deprivation (43) 43
radiotherapy (43) 43
aged, 80 and over (41) 41
castration (40) 40
disease progression (39) 39
progression (39) 39
prostate-specific antigen (39) 39
androgen deprivation therapy (38) 38
drug administration schedule (38) 38
testosterone - blood (38) 38
health aspects (37) 37
analysis (36) 36
hormone therapy (36) 36
orchiectomy (36) 36
quality-of-life (36) 36
antineoplastic agents, hormonal - administration & dosage (34) 34
chemotherapy (34) 34
time factors (34) 34
hormonal-therapy (32) 32
research (30) 30
survival (30) 30
androgen antagonists - adverse effects (29) 29
deprivation therapy (29) 29
prostatic neoplasms - surgery (29) 29
androgen deprivation (28) 28
animals (28) 28
androgen-deprivation therapy (27) 27
prostate (27) 27
gonadotropin-releasing hormone - agonists (25) 25
medicine & public health (25) 25
prospective studies (25) 25
prostatic neoplasms - mortality (25) 25
prostatic neoplasms - radiotherapy (25) 25
prognosis (24) 24
tumors (24) 24
combined modality therapy (23) 23
development and progression (23) 23
prostatectomy (23) 23
radiation-therapy (23) 23
antineoplastic agents, hormonal - adverse effects (22) 22
docetaxel (22) 22
endocrinology & metabolism (22) 22
trial (22) 22
follow-up studies (21) 21
antineoplastic agents - therapeutic use (20) 20
hormones (20) 20
blockade (19) 19
neoplasm staging (19) 19
retrospective studies (19) 19
flutamide (18) 18
intermittent androgen deprivation therapy (18) 18
intermittent therapy (18) 18
prospective phase-ii (18) 18
prostatic neoplasms - diagnosis (18) 18
drug therapy (17) 17
endocrine therapy (17) 17
growth (17) 17
psa (17) 17
receptor (17) 17
risk (17) 17
article (16) 16
disease-free survival (16) 16
hormonal therapy (16) 16
neoplasms, hormone-dependent - drug therapy (16) 16
oncology, experimental (16) 16
recurrence (16) 16
serum testosterone (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2019, Volume 125, Issue 3, pp. 453 - 462
Background Surgical and medical androgen deprivation therapy (ADT) strategies are comparable in their ability to suppress serum testosterone levels as... 
androgen deprivation therapy (ADT) | orchiectomy | cancer disparities | metastatic prostate cancer | SURVIVAL | DIAGNOSIS | INTERMITTENT | RACIAL DISPARITIES | TRENDS | INSURANCE STATUS | IMPACT | CALIFORNIA | ONCOLOGY | QUALITY-OF-LIFE | Ethnic Groups - statistics & numerical data | Prostatic Neoplasms - pathology | Prostatic Neoplasms - surgery | California - epidemiology | Humans | Middle Aged | European Continental Ancestry Group - statistics & numerical data | Hispanic Americans - statistics & numerical data | Male | Insurance Coverage - statistics & numerical data | Socioeconomic Factors | Prostatic Neoplasms - epidemiology | Practice Patterns, Physicians' - statistics & numerical data | Neoplasm Metastasis | Antineoplastic Agents, Hormonal - therapeutic use | Orchiectomy - statistics & numerical data | Androgen Antagonists - therapeutic use | Quality of Life | Registries | Aged | Prostatic Neoplasms - drug therapy | Health care | Identification methods | Medical services | Hispanic Americans | Social factors | Metastasis | Cancer therapies | Socioeconomics | Lymph nodes | Metastases | Confidence intervals | Surgery | Race | Military personnel | Diagnosis | Deprivation | Statistical analysis | Neighborhoods | Rural areas | Urban areas | Socio-economic aspects | Radiation therapy | Minority & ethnic groups | Patients | Quality of life | Testosterone | Ethnicity | Androgens | Chemotherapy | Government programs | Insurance | Prostate cancer | Prostate | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 5, pp. 722 - 730
Journal Article
European Urology, ISSN 0302-2838, 2009, Volume 55, Issue 6, pp. 1269 - 1277
Journal Article
ONCOLOGY NURSING FORUM, ISSN 0190-535X, 07/2019, Volume 46, Issue 4, pp. E107 - E118
PROBLEM IDENTIFICATION: To determine best practices for managing hot flashes associated with androgen deprivation therapy (ADT) in men with prostate cancer.... 
androgen deprivation therapy | PILOT EVALUATION | ACUPUNCTURE | SAFETY | NURSING | INTERMITTENT | FLUSHES | VENLAFAXINE | TRIAL | MEGESTROL-ACETATE | IMPACT | ONCOLOGY | hot flashes | complementary and alternative medicine
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 10/2018, Volume 38, Issue 10, pp. 999 - 1009
Study Objective To examine the risks and compare the occurrences of major long‐term side effects (sexual dysfunction, bone fractures, diabetes, cardiovascular... 
bone fractures | side effects | prostate cancer | androgen‐deprivation therapy | androgen-deprivation therapy | FRACTURE | IMPACT | METAANALYSIS | CARDIOVASCULAR-DISEASE | INTERMITTENT | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | HEALTH | Prostatic Neoplasms - pathology | SEER Program | Follow-Up Studies | Medicare | United States | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Proportional Hazards Models | Male | Combined Modality Therapy | Incidence | Prostatic Neoplasms - therapy | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Propensity Score | Aged, 80 and over | Aged | Retrospective Studies | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Cohort Studies | Complications and side effects | Oncology, Experimental | Research | Radiotherapy | Sexual disorders | Coronary heart disease | Epidemiology | Dementia | Cancer | Health care | Myocardial infarction | Heart | Radiation | Cardiovascular disease | Cancer therapies | Risk factors | Confidence intervals | Surgery | Risk assessment | Dementia disorders | Heart diseases | Deprivation | Diabetes mellitus | Health risks | Sexual behavior | Hazards | Radiation therapy | Patients | Coronary artery disease | Morbidity | Computer programs | Androgens | Side effects | Bone cancer | Fractures | Statistical models | Surveillance | Government programs | Infarction | Bone | Diabetes | Cardiovascular diseases | Health risk assessment | Prostate cancer | Prostate
Journal Article
The Prostate, ISSN 0270-4137, 05/2019, Volume 79, Issue 6, pp. 614 - 621
Background The anti‐cancer activities of curcumin are well‐documented from preclinical studies using prostate cancer models. Our objective was to evaluate the... 
intermittent androgen deprivation | prostate cancer | curcumin | ANALOGS | PREVENTION | PHASE-II | RECEPTOR | I CLINICAL-TRIAL | DOCETAXEL | THERAPY | MEN | GROWTH | ENDOCRINOLOGY & METABOLISM | UROLOGY & NEPHROLOGY | EXTRACT | Clinical trials | Testosterone | Cancer patients | Care and treatment | Prostate cancer | Analysis | Androgens | Curcumin | Patients | Prostate | Quality of life
Journal Article
JOURNAL OF UROLOGY, ISSN 0022-5347, 02/2017, Volume 197, Issue 2, pp. 398 - 399
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 69, Issue 4, pp. 720 - 727
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2016, Volume 14, Issue 5.5, pp. 663 - 665
Since its introduction more than 70 years ago, the use of androgen deprivation therapy (ADT) for prostate cancer has evolved to become part of a multimodal... 
TRIAL | METAANALYSIS | ONCOLOGY | INTERMITTENT | RADIOTHERAPY
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 06/2019, Volume 28, Issue 6, pp. 796 - 803
Journal Article
Journal Article